improv
core
measur
document
improv
actual
clinic
outcom
largest
random
control
trial
sever
cap
date
captiv
communityacquir
pneumonia
tifacogin
intraven
administr
trial
efficaci
trial
tissu
factor
pathway
inhibitor
sever
cap
clearli
neg
howev
studi
demonstr
feasibl
larg
clinic
trial
focus
sole
one
form
sever
sepsi
captiv
first
use
infecti
diseas
societi
americaamerican
thorac
societi
idsaat
criteria
sever
cap
defin
patient
appropri
clinic
trial
presenc
three
minor
criteria
sever
cap
associ
mortal
subsequ
develop
septic
shock
acut
respiratori
failur
subgroup
sever
cap
therefor
warrant
inclus
futur
trial
sever
cap
recombin
surfact
protein
c
aerosol
also
demonstr
effect
mortal
oxygen
durat
ventil
nonpulmonari
organ
failurefre
day
patient
sever
direct
lung
injuri
predominantli
pneumonia
aspir
unfortun
neg
result
may
result
partial
inactiv
surfact
aerosol
gener
may
explain
lack
oxygen
benefit
consist
seen
studi
pulmonari
deposit
surfact
two
neg
clinic
trial
combin
neg
prowess
recombin
human
activ
protein
c
worldwid
evalu
sever
sepsi
shock
trial
leav
clinician
clinic
investig
attempt
explain
neg
result
despit
posit
preliminari
trial
importantli
need
adjunct
supplement
therapi
addit
antibiot
reduc
mortal
rate
patient
sever
cap
demonstr
trial
although
pandem
abat
observ
influenza
infect
may
lesson
season
case
futur
epidem
wanzeck
colleagu
demonstr
glycosyl
hemagglutinin
influenza
result
lower
antibodi
respons
lack
neutral
antibodi
inabl
protect
mice
subsequ
challeng
less
glycosyl
strain
clinic
relev
recent
season
strain
heavili
glycosyl
mous
model
prior
infect
protect
pandem
influenza
strain
may
partial
explan
preponder
sever
diseas
young
adult
two
larg
multicent
studi
epidem
address
effect
corticosteroid
therapi
outcom
brunbuisson
colleagu
retrospect
analyz
steroid
treatment
prospect
french
cohort
influenza
patient
acut
respiratori
distress
syndrom
ard
kim
colleagu
retrospect
analyz
patient
influenza
patient
refer
academ
medic
center
korea
result
cohort
remark
similar
neither
demonstr
mortal
benefit
corticosteroid
found
higher
rate
secondari
bacteri
infect
particularli
pneumonia
studi
use
propensitytoreceivecorticosteroid
score
adjust
differ
baselin
characterist
addit
brunbuisson
colleagu
exclud
patient
indic
corticosteroid
asthma
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
effort
isol
effect
influenza
pneumonia
specif
despit
sever
limit
data
two
studi
provid
strong
evid
use
corticosteroid
pure
treatment
sever
influenza
pneumonia
pattern
consist
corticosteroid
case
seri
sever
viral
pneumonia
avian
influenza
sever
acut
respiratori
syndrom
sar
epidem
although
propon
readi
abandon
steroid
treatment
heterogen
group
patient
ard
result
two
studi
suggest
inclus
sever
viral
pneumonia
heterogen
ard
studi
may
actual
blunt
evid
benefici
corticosteroid
effect
rest
popul
anim
studi
suggest
potenti
altern
treatment
sever
influenza
pneumonia
transgen
mice
increas
granulocytemacrophag
colonystimul
factor
gmcsf
express
lung
protect
influenza
challeng
lethal
wildtyp
mice
intranas
gmcsf
influenza
inocul
also
rescu
wildtyp
mice
deplet
alveolar
macrophag
cell
b
cell
neutrophil
transgen
mice
result
loss
protect
effect
gmcsf
suggest
enhanc
alveolar
macrophag
function
contribut
protect
influenza
signific
barrier
clinic
use
gmcsf
sever
viral
pneumonia
discuss
accompani
editori
number
studi
suggest
inhal
steroid
use
patient
copd
increas
risk
pneumonia
although
risk
remain
controversi
mechan
unclear
concern
rais
possibl
two
public
address
issu
use
advers
event
report
industrysponsor
clinic
trial
obyrn
colleagu
could
demonstr
increas
risk
patient
asthma
use
inhal
corticosteroid
compar
placebo
also
found
differ
pneumonia
risk
budesonid
fluticason
dose
budesonid
chen
colleagu
report
flip
side
coin
use
veteran
administr
administr
databas
found
prior
use
inhal
steroid
patient
copd
admit
cap
associ
significantli
lower
risk
mortal
odd
ratio
need
mechan
ventil
differ
need
vasopressor
demonstr
result
may
explain
increas
allcaus
mortal
seen
despit
increas
risk
develop
cap
patient
copd
receiv
inhal
corticosteroid
chang
spectrum
pulmonari
diseas
patient
hiv
diseas
document
match
cohort
veteran
bacteri
pneumonia
still
four
five
time
like
hivposit
veteran
less
year
old
hivneg
patient
lower
ratio
older
patient
bacteri
pneumonia
remain
second
common
pulmonari
diagnosi
patient
hiv
diseas
rate
significantli
decreas
compar
histor
cohort
despit
hivposit
patient
may
still
benefit
conjug
pneumococc
vaccin
similar
pattern
seen
tuberculosi
pneumocysti
pneumonia
remain
mani
time
like
patient
hiv
diseas
longer
common
pulmonari
diagnosi
studi
clearli
document
increas
burden
noninfecti
pulmonari
disord
patient
hiv
diseas
includ
lung
cancer
copd
pulmonari
hypertens
new
associ
pulmonari
fibrosi
shift
spectrum
pulmonari
disord
era
highli
activ
antiretrovir
therapi
age
hivposit
popul
parallel
indic
hiv
diseas
becom
chronic
diseas
affect
multipl
organ
two
offici
at
statement
deal
pneumonia
immunocompromis
host
publish
year
offici
at
statement
treatment
fungal
diseas
adult
distinguish
care
immunocompet
immunosuppress
patient
recommend
antifung
treatment
manag
strategi
offici
at
research
statement
review
current
state
knowledg
regard
idiopath
pneumonia
syndrom
stem
cell
transplant
frequent
treat
infecti
better
understand
pathogenesi
like
lead
new
potenti
intervent
sinc
benefit
corticosteroid
therapi
remain
controversi
novel
treatment
modal
clearli
need
immunocompromis
patient
respiratori
syncyti
viru
rsv
infect
independ
risk
factor
bronchiol
obliteran
syndrom
bo
acut
reject
graft
failur
death
lung
transplant
recipi
aerosol
small
interf
rna
bind
messeng
rna
nucleocapsid
gene
rsv
induc
cleavag
studi
small
random
placebocontrol
trial
lung
transplant
recipi
rsvonli
infect
clinic
symptom
score
importantli
incid
new
bo
lower
treat
patient
patient
receiv
placebo
vs
p
astor
review
promis
new
therapeut
approach
discuss
use
rsv
transplant
recipi
appear
model
infect
new
class
therapeut
agent
nosocomi
pneumonia
hospitalacquir
pneumonia
ventilatorassoci
pneumonia
healthcareassoci
pneumonia
nosocomi
pneumonia
remain
common
concern
hospit
patient
sever
investig
inflammatori
respons
lung
infect
help
us
better
understand
gramneg
pneumonia
lead
advers
consequ
acut
lung
injuri
ali
herold
colleagu
observ
ccchemokin
defici
mice
lack
exud
macrophag
lead
ali
lp
challeng
howev
intratrach
receptor
antagonist
enhanc
surviv
experiment
gramneg
pneumonia
find
indic
exud
macrophag
protect
lung
injuri
upregul
hand
studi
sepsi
pneumonia
anim
also
less
inflammatori
respons
protect
mortal
benefit
understand
host
inflammatori
respons
pneumonia
potenti
discoveri
novel
biomark
infect
infect
prognosi
serkova
colleagu
review
field
metabolom
examin
import
metabolit
detect
gene
function
protein
product
use
method
mass
spectroscopi
type
approach
may
use
determin
etiolog
pneumonia
differ
bacteri
pathogen
may
differ
metabol
profil
even
greater
differ
viral
infect
exampl
pseudomona
aeruginosa
pathogenesi
particularli
mediat
exoproduct
product
wargo
colleagu
demonstr
phospholipas
csphingomyelinas
pcplcsmase
led
loss
lung
function
mous
model
p
aeruginosa
pneumonia
reduc
anim
infect
exoproductdefici
strain
system
miltefosin
act
substrat
phospholipas
c
also
protect
exoproductinduc
loss
lung
function
find
may
lead
therapi
amelior
develop
ali
patient
p
aeruginosa
pneumonia
common
caus
ventilatorassoci
pneumonia
vap
one
current
controversi
whether
alreadi
effect
identifi
risk
factor
vap
abl
devis
prevent
strategi
lead
zero
vap
howev
prevent
vap
may
import
outcom
patient
intens
care
unit
icu
previous
thought
data
suggest
impact
mortal
occur
french
multicent
studi
ventil
patient
compar
outcom
acquir
vap
mortal
rate
patient
vap
versu
patient
without
vap
thu
show
mortal
impact
vap
small
author
differenti
studi
result
other
account
chang
sever
ill
time
use
margin
structur
model
surviv
analysi
although
provoc
find
answer
number
question
particularli
concern
impact
therapi
mortal
inform
rate
appropri
therapi
provid
popul
littl
methicillinresist
staphylococcu
aureu
mrsa
nearli
nonfer
gramneg
pathogen
treat
effect
say
vap
impact
mortal
would
mislead
mortal
would
certainli
occur
therapi
wrong
therapi
given
accompani
editori
defici
note
includ
lack
diagnost
gold
standard
patient
vap
may
misclassifi
vap
thu
underestim
attribut
mortal
diseas
sever
investig
expand
understand
vap
risk
factor
examin
role
gastropulmonari
rout
pathogen
acquisit
tri
interrupt
rout
via
mainten
endotrach
tube
cuff
pressur
tri
prevent
prolong
intub
use
noninvas
ventil
facilit
wean
although
noninvas
ventil
effect
reduc
postextub
respiratori
failur
death
significantli
reduc
incid
nosocomi
pneumonia
compar
convent
wean
interest
endotrach
tube
cuff
renew
mainten
adequ
pressur
avoid
aspir
oropharyng
secret
lung
attent
composit
polyurethan
prefer
polyvinylchlorid
shape
possibl
valu
taper
cuff
shape
one
interest
risk
factor
earlyonset
vap
emerg
use
therapeut
hypothermia
follow
outofhospit
cardiac
arrest
ohca
french
investig
examin
incid
pneumonia
within
day
ohca
popul
widespread
use
therapeut
hypothermia
ohca
incid
earlyonset
pneumonia
eop
patient
ohca
use
microbiolog
sampl
patient
therapeut
hypothermia
singl
independ
risk
factor
eop
multivari
analysi
rais
risk
almost
twofold
although
eop
increas
risk
subsequ
vap
poor
neurolog
outcom
mortal
durat
mechan
ventil
icu
length
stay
increas
accompani
editori
note
although
bacteriolog
commonli
involv
commun
pathogen
patient
surprisingli
harbor
resist
pathogen
pneumonia
incid
high
popul
valu
short
cours
prophylact
antibiot
patient
ohca
treat
hypothermia
may
worth
studi
also
need
greater
understand
biolog
effect
hypothermia
although
hypothermia
predispos
pneumonia
hypothermia
protect
bacteri
dissemin
appli
onset
pneumococc
pneumonia
anim
model
prevent
sepsisinduc
mitochondri
dysfunct
episod
pneumonia
result
microaspir
bacteria
present
oropharynx
lung
demonstr
healthi
lower
respiratori
tract
contain
organ
oropharynx
lower
number
situat
ill
may
vari
point
studi
stomach
sourc
pathogen
reach
lung
caus
pneumonia
possibl
ventil
patient
organ
directli
inocul
lung
surround
environ
organ
caus
nosocomi
pneumonia
increasingli
multidrugresist
mdr
pathogen
studi
bacteriolog
hospitalacquir
pneumonia
hap
vap
asian
countri
involv
hospit
mdr
pathogen
common
treat
incorrectli
led
increas
mortal
common
pathogen
aureu
follow
acinetobact
speci
p
aeruginosa
klebsiella
pneumonia
resist
common
countri
studi
uniqu
bacteriolog
featur
vap
acinetobact
patient
common
follow
p
aeruginosa
aureu
mdr
pathogen
occur
outsid
icu
even
present
patient
eop
identifi
mdr
risk
factor
methicillin
resist
present
aureu
isol
acinetobact
speci
p
aeruginosa
resist
carbapenem
alarm
data
indic
countri
icu
need
know
local
microbi
pathogen
design
effect
empir
therapi
especi
discord
therapi
increas
mortal
unfortun
effect
agent
pathogen
acinetobact
speci
colistin
emphas
urgent
need
new
agent
activ
mdr
gramneg
mention
hap
vap
often
due
mdr
gramneg
treatment
pathogen
exist
agent
limit
set
use
adjunct
aerosol
antibiot
may
valuabl
one
bold
studi
compar
aerosol
therapi
vap
ceftazidim
amikacin
without
intraven
therapi
intraven
ceftazidim
amikacin
therapi
random
studi
patient
patient
suscept
intermedi
sensit
p
aeruginosa
efficaci
regimen
compar
earli
erad
pathogen
greater
abil
erad
intermedi
suscept
pathogen
aerosol
group
recurr
infect
occur
aerosoltr
patient
versu
compar
patient
use
vibrat
mesh
plate
nebul
led
greater
retent
lung
expiratori
line
filter
becam
obstruct
three
patient
one
transient
cardiac
arrest
although
find
promis
given
current
challeng
mdr
pathogen
aerosol
therapi
like
use
adjunct
intraven
therapi
suggest
result
anoth
blind
studi
past
year
sever
studi
examin
impact
atsidsa
guidelin
manag
hap
vap
healthcareassoci
pneumonia
hcap
one
controversi
studi
vap
n
haphcap
n
conclud
patient
receiv
therapi
compliant
guidelin
increas
mortal
number
issu
limit
full
accept
conclus
includ
observ
appropri
therapi
lead
improv
surviv
patient
infect
p
aeruginosa
mrsa
addit
definit
compliant
therapi
consid
deescal
often
done
time
dose
appropri
therapi
controversi
regard
use
nosocomi
pneumonia
antibiot
regimen
patient
hcap
also
amplifi
last
year
studi
unit
state
canada
unit
kingdom
indic
mani
patient
hcap
success
treat
cap
regimen
broader
spectrum
regimen
may
harm
heterogen
patient
hcap
increasingli
clear
correct
approach
probabl
depend
patient
risk
factor
mdr
pathogen
fact
ventil
bundl
although
use
may
realist
lead
zero
vap
indic
need
addit
routin
measur
mainten
cuff
pressur
cm
h
continu
control
devic
effect
reduc
vap
use
intermitt
rather
continu
subglott
secret
drainag
howev
import
note
although
intervent
benefici
vap
rate
reduc
zero
subglott
secret
drainag
reduc
lateonset
vap
rate
continu
mainten
cuff
pressur
reduc
vap
rate
use
bundl
method
reduc
vap
robust
method
implement
monitor
use
intervent
import
prompt
enhanc
adher
use
daili
checklist
recommend
process
care
may
improv
use
antibiot
impact
mortal
aecopd
often
treat
singl
entiti
use
unbias
statist
tool
bafadhel
cowork
abl
classifi
aecopd
four
biolog
clustersbacteri
viral
eosinophil
pauciinflammatoryand
defin
biomark
character
cluster
baselin
biomark
data
predict
eosinophil
bacteri
exacerb
viral
exacerb
cluster
could
distinguish
anthonisen
criteria
use
extens
registr
trial
indic
bacteri
aecopd
easiest
clinic
biomark
peripher
eosinophilia
defin
eosinophil
exacerb
although
biomark
use
defin
cluster
easili
obtain
current
abil
distinguish
type
aecopd
like
increas
correct
manag
although
trial
demonstr
approach
yet
complet
rhinoviru
common
document
caus
aecopd
viruspredomin
studi
bafadhel
colleagu
experiment
exposur
studi
document
rhinoviru
clearli
caus
symptomatolog
aecopd
patient
copd
appear
impair
ifng
respons
bal
cell
compar
normal
peopl
expos
rhinoviru
patient
asthma
also
increas
risk
exacerb
rhinoviru
infect
even
infant
increas
airway
resist
like
wheez
infect
rhinoviru
thu
rhinoviru
join
rsv
major
caus
wors
bronchospasm
patient
underli
obstruct
lung
diseas
contrast
virus
appear
play
major
role
acut
exacerb
pulmonari
fibrosi
despit
extens
search
author
disclosur
avail
text
articl
wwwatsjournalsorg
